Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

SOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the...
March 31, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the...
March 27, 2025 08:15 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN...
November 15, 2024 08:45 ET | Source: CERo Therapeutics Holdings, Inc.

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of...
November 01, 2024 08:00 ET | Source: Envoy Medical, Inc

Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device

The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE...
September 09, 2024 08:30 ET | Source: Femasys Inc.

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
August 29, 2024 08:30 ET | Source: BioCardia, Inc.

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
August 26, 2024 09:15 ET | Source: FMW Media Works Corp

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT

New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT
August 21, 2024 07:00 ET | Source: BioCardia, Inc.

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
August 09, 2024 09:30 ET | Source: FMW Media Works Corp

New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET

New to The Street TV Announces Episode 583, Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024

Next Page keyboard_arrow_right